DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Dr Varitsara Mangkorntongsakul, Senior Medical Officer, Central Coast Local Health District, NSW, Australia. Dr Yi Jia Lee, Junior Medical Officer, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. Technical Editor: Mary-Elaine Luther, medical student, Ross University School of Medicine, Barbados. DermNet NZ Editor in Chief: Adjunct A/Prof. Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. January 2020.
Cannabis refers to one of two notable subspecies of the cannabis plant.
Cannabis is also known as pot, weed, hash, dope, ganja, joint, stick, yarndi, cone, mull, 420, dabs, dabbing, BHO, choof, and mull [1,2].
Cannabis comes in various forms .
Cannabinoid refers to any chemical substance that binds to the cannabinoid receptors CB1 and CB2 in the body producing similar effects to C. sativa. There are three types of cannabinoid [1,3].
Cannabis can be smoked, ingested (eaten), or vaporised to induce a temporary state of euphoria and sense of relaxation . The psychoactive properties of cannabis are primarily due to THC; THC concentration is commonly used as a measure of cannabis potency.
Endogenous and exogenous cannabinoids activate the cannabinoid receptors CB1 and CB2 [2–4].
Activation of the CB1 receptor results in:
Topical cannabinoids are creams, patches, and gels containing plant-derived, endogenous, or synthetic cannabinoids that are intended for therapeutic use .
Experimentally, creams containing PEA and synthetic cannabinoids have been shown to be effective and well-tolerated in the treatment of itch associated with atopic dermatitis, lichen simplex, nodular prurigo, and uraemia [3,6,11].
Cannabinoids have immunosuppressive, anti-inflammatory, and other properties that may be useful in the treatment of inflammatory skin diseases, such as various forms of dermatitis, psoriasis, follicular disorders, and scleroderma [3,5,10,11].
The role of cannabinoids in skin cancer is confusing.
UVA and UVB can activate inflammation through the endocannabinoid system, thus potentially accelerating the initial stages of oncogenic transformation . Cannabinoids can also promote oncogenic viral transformation as a result of their immunosuppressive properties [5,10].
However in animal models cannabinoids have been found to have anti-tumour effects mediated by both the CB1 receptor and especially the CB2 receptor. These anti-tumour effects are expressed on melanoma and keratinocyte cancers, resulting in the induction of apoptosis in tumours but not of normal melanocytes, and inhibition of [3,5,9]:
Oral cannabinoids have been used in the treatment of cancer-related side effects such as chemotherapy-induced nausea and vomiting, pain, and poor appetite.
Cannabis extracts have shown the following benefits for multiple sclerosis:
Cannabis extracts have also shown be beneficial in the treatment of chronic pain [4,8,12].
Other potential positive effects of cannabinoids include reducing the following:
Further studies are required to explore the potential benefits of medical cannabis for the treatment of the following conditions [4,8,12]:
Potential side effects and safety of topical cannabinoids have not been well elucidated. Some of the systemic effects of oral cannabinoids are listed below [4,12,13]:
|Neurological||Memory impairment, tremors, seizures|
|Anxiety, confusion, agitation, mood dysregulation, paranoia, psychosis (short-term and long-term), suicidal ideation, perceptual disturbances|
|Diaphoresis, chest pain, acute myocardial infarction, hypertension, tachycardia|
|Gastrointestinal||Cannabinoid hyperemesis syndrome: abdominal pain, nausea, and vomiting; symptoms can be relieved with a warm shower|
|Cannabinoid sensitisation or allergy; cannabis arteritis: severe vascular disease, leading to limb loss (see Thromboangiitis obliterans)|
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.